EGFR20ins突变临床前药物研发模型

靶点背景介绍

EGFR第20号外显子插入突变，简称EGFR20ins，约占EGFR突变的4-12%。EGFR20ins对EGFR-TKI耐药（p.A763_Y764insFQEA除外）。临床无标准的靶向治疗方案可用。靶向治疗处于临床试验阶段，其中包括EGFR单抗联合TKI，以及对EGFR20ins有高活性或者高选择性的新型小分子药物，例如Poziotinib 、TAK-788等。[1-5]

现有模型介绍

EGFR20ins突变类器官模型

EGFR20ins突变细胞系模型

科途医学已经建立以上EGFR20ins突变的非小细胞肺癌类器官和细胞系药理模型，EGFR20ins临床前模型数量仍在不断快速扩充中。如需使用上述类器官或细胞系模型进行药物研发和商业合作，欢迎联系我们。

参考文献

1.Fang, W., et al., Durable Response of Low-Dose Afatinib plus Cetuximab in an Adenocarcinoma Patient with a Novel EGFR Exon 20 Insertion Mutation. J Thorac Oncol, 2019. 14(10): p. e220-e221.

2.Robichaux, J.P., et al., Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. Nat Med, 2018. 24(5): p. 638-646.

3.Hasako, S., et al., TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther, 2018. 17(8): p. 1648-1658.

4.Udagawa, H., et al., TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations. Mol Cancer Res, 2019. 17(11): p. 2233-2243.

5.Vyse, S. and P.H. Huang, Targeting EGFR exon 20 insertion mutations in non-small cell lung cancer. Signal Transduct Target Ther, 2019. 4: p. 5.